Shankar-Hari, Manu, Kruger, Peter S., Di Gangi, Stefania, Scales, Damon C., Perkins, Gavin D., McAuley, Danny F. and Terblanche, Marius. (2012) Statin therapy in critical illness : an international survey of intensive care physicians' opinions, attitudes and practice. BMC Clinical Pharmacology, Vol.12 (No.1). p. 13. ISSN 1472-6904

Preview	Text (Article) WRAP_Perkins_1472-6904-12-13.pdf Download (322Kb) | Preview
Preview	Text (Cover sheet) WRAP_Perkins_1472-6904-12-13.pdf Download (357Kb) | Preview

Abstract

Background Pleotropic effects of statins on inflammation are hypothesised to attenuate the severity of and possibly prevent the occurrence of the host inflammatory response to pathogen and infection-related acute organ failure. We conducted an international survey of intensive care physicians in Australia, New Zealand (ANZ) and United Kingdom (UK). The aims of the survey were to assess the current prescribing practice patterns, attitudes towards prescribing statin therapy in critically ill patients and opinions on the need for an interventional trial of statin therapy in critically ill patients. Methods Survey questions were developed through an iterative process. An expert group reviewed the resulting 26 items for face and content validity and clarity. The questions were further refined following pilot testing by ICU physicians from Australia, Canada and the UK. We used the online Smart SurveyTM software to administer the survey. Results Of 239 respondents (62 from ANZ and 177 from UK) 58% worked in teaching hospitals; most (78.2%) practised in ‘closed’ units with a mixed medical and surgical case mix (71.0%). The most frequently prescribed statins were simvastatin (77.6%) in the UK and atorvastatin (66.1%) in ANZ. The main reasons cited to explain the choice of statin were preadmission prescription and pharmacy availability. Most respondents reported never starting statins to prevent (65.3%) or treat (89.1%) organ dysfunction. Only a minority (10%) disagreed with a statement that the risks of major side effects of statins when prescribed in critically ill patients were low. The majority (84.5%) of respondents strongly agreed that a clinical trial of statins for prevention is needed. More than half (56.5%) favoured rates of organ failure as the primary outcome for such a trial, while a minority (40.6%) favoured mortality. Conclusions Despite differences in type of statins prescribed, critical care physicians in the UK and ANZ reported similar prescription practices. Respondents from both communities agreed that a trial is needed to test whether statins can prevent the onset of new organ failure in patients with sepsis.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School > Institute of Clinical Education (ICE)
Library of Congress Subject Headings (LCSH):	Statins (Cardiovascular agents), Critical care medicine
Journal or Publication Title:	BMC Clinical Pharmacology
Publisher:	Bio Med Central
ISSN:	1472-6904
Date:	2012
Volume:	Vol.12
Number:	No.1
Page Range:	p. 13
Identification Number:	10.1186/1472-6904-12-13
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Funder:	Canadian Institutes of Health Research (CIHR), National Institute for Health Research (Great Britain) (NIHR)
References:	1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31(4):1250–1256. 2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348 (16):1546–1554. 3. Harrison DA, Welch CA, Eddleston JM: The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006, 10(2):R42. 4. Linde-Zwirble WT, Angus DC: Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004, 8(4):222–226. 5. Angus DC, Wax RS: Epidemiology of sepsis: an update. Crit Care Med 2001, 29(7 Suppl):S109–S116. 6. Burchardi H, Schneider H: Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics 2004, 22(12):793–813. 7. Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, Shapiro N: The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 2008, 36(4):1168–1174. 8. Cinel I, Opal SM: Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009, 37(1):291–304. 9. Phillip Dellinger R, Parrillo JE: Mediator modulation therapy of severe sepsis and septic shock: does it work? Crit Care Med 2004, 32(1):282–286. 10. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344(10):699–709. 11. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R: Intensive insulin therapy in the medical ICU. New England Journal of Medicine 2006, 354 (5):449–461. 12. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically Ill patients. New England Journal of Medicine 2001, 345 (19):1359–1367. 13. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O'Kane CM, Elborn JS, McAuley DF: A randomized clinical trial of hydroxymethylglutarylcoenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med 2011, 183(5):620–626. 14. Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, Venkatesh B: Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011, 183(6):774–781. 15. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L: Costeffectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation 2011, 124(2):146–153. 16. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG: Statins and sepsis: multiple modifications at multiple levels. The Lancet Infectious Diseases 2007, 7(5):358–368. 17. Jasinska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007, 59(5):483–499. 18. Terblanche M, Smith TS, Adhikari NK: Statins, bugs and prophylaxis: intriguing possibilities. Crit Care 2006, 10(5):168. 19. Shyamsundar M, McKeown STW, O'Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, et al: Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. American Journal of Respiratory and Critical Care Medicine 2009, 179(12):1107–1114. 20. Wilding EI, Brown JR, Bryant AP, Chalker AF, Holmes DJ, Ingraham KA, Iordanescu S, So CY, Rosenberg M, Gwynn MN: Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci. J Bacteriol 2000, 182(15):4319–4327. 21. Chow OA, von Kockritz-Blickwede M, Bright AT, Hensler ME, Zinkernagel AS, Cogen AL, Gallo RL, Monestier M, Wang Y, Glass CK, et al: Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 2010, 8 (5):445–454. 22. Bergman P, Linde C, Putsep K, Pohanka A, Normark S, Henriques-Normark B, Andersson J, Bjorkhem-Bergman L: Studies on the antibacterial effects of statins–in vitro and in vivo. PLoS ONE 2011, 6(8):e24394. 23. Masadeh M, Mhaidat N, Alzoubi K, Al-Azzam S, Alnasser Z: Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin. Ann Clin Microbiol Antimicrob 2012, 11(1):13. 24. Welsh AM, Kruger P, Faoagali J: Antimicrobial action of atorvastatin and rosuvastatin. Pathology 2009, 41(7):689–691. 25. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI: Statins for infection and sepsis: a systematic review of the clinical evidence. Journal of Antimicrobial Chemotherapy 2008, 61(4):774–785. 26. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T: Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009, 169(18):1658–1667. 27. Douglas I, Evans S, Smeeth L: Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011, 342:d1642. 28. Björkhem-Bergman L, Bergman P, Andersson J, Lindh JD: Statin treatment and mortality in bacterial infections – a systematic review and metaanalysis. PLoS ONE 2010, 5(5):e10702. 29. Truwit JD: Statins: a role in infected critically ill patients? Crit Care 2011, 15(2):145. 30. Terblanche MJ, Pinto R, Whiteley C, Brett S, Beale R, Adhikari NK: Statins do not prevent acute organ failure in ventilated ICU patients: single-centre retrospective cohort study. Crit Care 2011, 15(1):R74. 31. Feinstein AR: Chapter 10: The Theory and Evaluation of Sensibility. Yale University Press: Clinimetrics. New Haven; 1987. 32. Smart-SurveyTM. Smart-SurveyTM. http://www.smart-survey.co.uk. 33. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, et al: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360(13):1283–1297. 34. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, et al: Intensity of continuous renalreplacement therapy in critically ill patients. N Engl J Med 2009, 361 (17):1627–1638. 35. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350(22):2247–2256. 36. Burns KEA, Duffett M, Kho ME, Meade MO, Adhikari NKJ, Sinuff T, Cook DJ: Group ftA: a guide for the design and conduct of self-administered surveys of clinicians. Canadian Medical Association Journal 2008, 179 (3):245–252.
URI:	http://wrap.warwick.ac.uk/id/eprint/49249

Request changes to a record

Actions (login required)

View Item